762
Views
6
CrossRef citations to date
0
Altmetric
Diabetes

The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes

, , , &
Pages 1167-1174 | Received 21 Apr 2016, Accepted 28 Jun 2016, Published online: 09 Aug 2016

References

  • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
  • Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in diabetes. Diabetes Care 2014;37:2763-73
  • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
  • Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
  • Pollack MF, Purayidathil FW, Bolge SC, et al. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Prac 2010;87:204-10
  • McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9.
  • Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
  • Granström O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes 2012;6:127-36
  • van Haalen HGM, Pompen M, Bergenheim K, et al. Cost-effectiveness of dapagliflozin as add-on to insulin for the treatment of type 2 diabetes in the Netherlands. Value Health 2013;16:A441
  • Palmer AJ, Clarke P, Gray A, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health J Int Soc Pharmacoeconom Outcomes Res 2013;16:670-85
  • Department of Health. Health Survey for England; 2003. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publicationsandstatistics/publications/publicationsstatistics/dh_4098712. Accessed September 15, 2014
  • Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5
  • Statistics Sweden (SCB). Swedish consumer price index (health component). 2015. http://www.scb.se/en_/Finding-statistics/Statistics-by-subject-area/Prices-and-Consumption/Consumer-Price-Index/Consumer-Price-Index-CPI/Aktuell-Pong/33779/Consumer-Price-Index-CPI/33907/. Accessed September 15, 2015
  • Federal Reserve. Foreign Exchange Rates - G.5A Annual. 2014. http://www.federalreserve.gov/releases/G5a/current/default.htm. Accessed September 15, 2015
  • Dental and Pharmaceutical Benefits Agency. Medication price list. 2015. http://www.tlv se/. Accessed November 17, 2015
  • Apoteket AB. Medication price list. 2015. http://www.apoteket.se. Accessed November 17, 2015
  • Gerdtham UG, Clarke P, Hayes A, et al. Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics 2009;27:81-90
  • Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248:387-96
  • Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9:193-8
  • Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
  • Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
  • Bagust A, Beale S. Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data. Health Econ 2005;14:217-30
  • Jaime Caro J, Ozer Stillman I, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007;10:239-54
  • Kiadaliri AA, Gerdtham UG, Eliasson B, et al. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. Diabetes Ther Res Treat Educ Diabetes Relat Dis 2014;5:591-607
  • Malhan S, Güler S, Yetkin I, et al. Cost-effectiveness of exenatide twice daily (bid) added to basal insulin compared to a bolus insulin add-on in Turkey. Proceedings of the ISPOR 17th Annual European Congress, Vol. 17, A349. Value in Health, Amsterdam, The Netherlands, November 8–12, 2014
  • Sánchez-Covisa J, Capel M, Baeten S, et al. Comparative cost-effectiveness analysis of adding twice-daily exenatide to insulin glargine versus adding insulin lispro to treat type 2 diabetes in Spain. Proceedings of the ISPOR 17th Annual European Congress, Vol. 17, A349–A350. Value in Health, Amsterdam, The Netherlands, November 8–12, 2014
  • Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009;52:65-73
  • National Institute for Health and Care Excellence. Clinical Guideline 87. Type 2 diabetes: The management of type 2 diabetes. 2009. http://www.nice.org.uk/Guidance/CG87. Accessed September 15, 2014
  • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
  • Asche CV, Bode B, Busk AK, et al. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:47-57
  • Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-17
  • Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes 2015;9:39-47.
  • Bristol-Myers Squibb Pharmaceuticals Ltd & Eli Lilly and Company. Final Clinical Study Report: H8O-EW-GWDM. A randomized trial comparing two therapies: Basal insulin glargine, exenatide and metformin therapy (BET) or basal insulin glargine, bolus insulin lispro and metformin therapy (BBT) in subjects with type 2 diabetes who were previously treated by basal insulin glargine with either metformin or metformin and sulfonylurea (4B: basal insulin glargine, exenatide BID, and metformin therapy or basal insulin glargine, bolus insulin lispro and metformin therapy). Indianapolis (Indiana, USA); 2013
  • Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
  • Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
  • Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.